Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 601 - 625 of 673 Clear search
Zyme Communications
11 Aug 2021

Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial

Cambridge and Wetherby... Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.

Zyme Communications
10 Aug 2021

FUJIFILM Irvine Scientific becomes sole worldwide distributor of Presagen’s Life Whisperer

High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection.

Zyme Communications
10 Aug 2021

Dotmatics to deliver the foundation for Croda’s R&D digital programme: artificial intelligence and data mining

Bishop’s Stortford, UK... Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Croda International Plc to implement its Research and Development (R&D) digital programme. Croda is the name behind the high-performance ingredients…

Zyme Communications
27 Jul 2021

ERS Genomics and Japan SLC sign CRISPR/Cas9 licence agreement

Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models.

Zyme Communications
20 Jul 2021

Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business

Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million (USD) in funding.

Zyme Communications
19 Jul 2021

Dotmatics announces support for AWS for Health initiative

Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, announced support for the AWS for Health initiative from Amazon Web Services (AWS) to improve laboratory efficiency and accelerate the pace of scientific innovation by facilitating more rapid data access, analysis and…

Zyme Communications
19 Jul 2021

Mologic to become a ‘social enterprise’ after acquisition by social impact funders and investors

A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, is today announcing the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the…

Zyme Communications
15 Jul 2021

H.E.L Group strengthens operations in North America

London, UK, 15 July 2021: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has expanded its operations in North America, with the establishment of a West Coast hub in California, and a Central Region hub in Missouri.

Zyme Communications
15 Jul 2021

Bio-Rad launches its Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit in Europe

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.

Zyme Communications
14 Jul 2021

Avacta’s Diagnostic Division achieves ISO 13485 certification

Cambridge and Wetherby, UK, 14 July 2021: Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for…

Zyme Communications
07 Jul 2021

Gyros Protein Technologies and Cygnus Technologies expand collaboration

Uppsala, Sweden, 07 July 2021: Gyros Protein Technologies (part of Mesa Labs’ Biopharmaceutical Development Division), a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the next phase of its on-going collaboration with Cygnus Technologies, a Maravai LifeSciences company, and the introduction of a new HEK 293 HCP…

Zyme Communications
01 Jul 2021

Birmingham University and Nonacus partner to develop urine test for bladder cancer

Birmingham, UK, 01 July 2021: Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer.

Zyme Communications
01 Jul 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 licence agreement

Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and Nippon Gene Co Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive licence…

Zyme Communications
01 Jul 2021

FairJourney Biologics introduces 'THE ANTIBODY SERIES' Conference

FairJourney Biologics SA (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” - a one-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery.

Zyme Communications
29 Jun 2021

CrestOptics selected by Akoya Biosciences for spatial biology collaboration

Rome, IT, 29 June 2021: CrestOptics SpA,  a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc, (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications.

Zyme Communications
29 Jun 2021

Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test detects Delta variant

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are…

Zyme Communications
29 Jun 2021

Orbit Discovery appoints Dr Neil Butt as Chief Executive Officer

Oxford, UK, June 29, 2021: Orbit Discovery Ltd, a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.

Zyme Communications
29 Jun 2021

Optibrium publishes major peer-reviewed study on AI applications to global pharma data

Published in AI Letters, study collaborators Optibrium, Takeda and Intellegens demonstrated the application of deep learning imputation to a global pharma dataset, offering new insights into drug discovery data that transform how complex data can be used to identify opportunities for new drugs and streamline the drug discovery process.

Zyme Communications
22 Jun 2021

LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-drug conjugates

Newcastle, UK, 22 June, 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and Licence Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.

Zyme Communications
21 Jun 2021

Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test distribution agreement

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc, a global provider of life science products, for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK…

Zyme Communications
15 Jun 2021

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

Oxford, UK: The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards. The award recognises the Company’s outstanding contribution to the fight against COVID-19.

Zyme Communications
14 Jun 2021

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy, ETD001. The first-in-man safety study is being…

Zyme Communications
14 Jun 2021

Avacta announces registration of its AffiDX SARS-CoV-2 antigen lateral flow test in EU

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU allowing the Company to place the product on the market in all 27 countries of the EU for professional use.

Zyme Communications
08 Jun 2021

Bio-Rad introduces three StarBright dyes for flow cytometry

The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 dyes offer precise excitation and emission spectra for improved brightness and resolution.

Zyme Communications
07 Jun 2021

ERS Genomics and genOway enter CRISPR/Cas9 agreement

Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and genOway, a leader in conceiving and developing genetically engineered preclinical research models, today announced a non-exclusive licence agreement granting genOway past and future access to…

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 23
  • Page 24
  • Current page 25
  • Page 26
  • Page 27
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS